Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaudfontaine – page 27

1 393 clinical trials in Chaudfontaine, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaudfontaine at a glance
1 393
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 393 trials in Chaudfontaine

Open in trial search

Cardiac arrest+3

Recruiting

Study of anti-seizure drug combination in comatose patients with status epilepticus after cardiac arrest

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Diazepam
  • Sponsor:Universiteit Twente

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Pancreatectomy

Recruiting

Study on Hydrocortisone for Patients Undergoing Pancreatic Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Technische Universitat Dresden

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Rectal cancer

Recruiting

Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Colitis ulcerative+1

Recruiting

Study on Reducing Vedolizumab Dosage for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Vedolizumab
  • Sponsor:Amsterdam UMC Stichting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Breast cancer+1

Recruiting

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Universitaetsklinikum Ulm AöR

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaudfontaine

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The research examines alternative approaches for managing functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Alternative Treatment Strategies

The study explores on-demand medication protocols and alternative therapeutic options, including alginate formulations, to improve patient care in primary healthcare settings.

02 Primary Care Innovation

Research evaluating optimal medication management strategies for patients with heartburn and reflux conditions. The study aims to establish evidence-based approaches for reducing long-term medication dependence.

  • Medication Optimization
  • Patient-Centered Care
  • Treatment Effectiveness

This investigation compares different therapeutic approaches to help healthcare providers make informed decisions about long-term medication management.

03 Therapeutic Management

A comprehensive evaluation of deprescribing strategies in primary care, comparing traditional dose reduction methods with innovative approaches to medication management.

  • Clinical Effectiveness
  • Patient Safety
  • Quality of Care

The research focuses on developing evidence-based protocols for transitioning patients from long-term medication use to more appropriate treatment regimens.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.